Cost effectiveness and quality of life considerations in the treatment of hepatitis C infection

ClinicoEconomics and Outcomes Research

Volumn 2, Issue 1, 2010, Pages 87-96

  Jafferbhoy, H ^a   Gashau, W ^a   Dillon, J F ^a  

^a UNIVERSITY OF DUNDEE   (United Kingdom)

Author keywords

Cost effective; Hepatitis C; Quality of life

Indexed keywords

ALPHA INTERFERON; ALPHA2A INTERFERON; ERYTHROPOIETIN; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RIBAVIRIN;

ANEMIA; ANTIVIRAL ACTIVITY; ARTHRALGIA; CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DEPRESSION; DERMATITIS; DISEASE COURSE; DOSE RESPONSE; DRUG ABUSE; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG INDUCED HEADACHE; DRUG WITHDRAWAL; FATIGUE; FEVER; FLU LIKE SYNDROME; GENOTYPE; HAIR LOSS; HEMATOLOGIC DISEASE; HEMOLYTIC ANEMIA; HEPATITIS C; HEPATITIS C VIRUS; HUMAN; IMMUNOMODULATION; INSOMNIA; MENTAL DISEASE; METHADONE TREATMENT; MOOD CHANGE; MYALGIA; NAUSEA; NEUTROPENIA; NONHUMAN; PREVALENCE; PRURITUS; QUALITY OF LIFE; REVIEW; RIGOR; RISK FACTOR; SHORT FORM 36; SIDE EFFECT; SUICIDAL IDEATION; THROMBOCYTOPENIA; VIRUS TRANSMISSION; WEAKNESS;

EID: 77955454892     PISSN: None     EISSN: 11786981     Source Type: Journal    
DOI: None     Document Type: Review

References (72)

1. Mühlberger NSR, Lettmeier B, Sroczynski G, Zeuzem S, Siebert U. HCV-related burden of disease in Europe: a systematic assessment of incidence, prevalence m, and mortality. BMC Public Health. 2009 Jan 22;9:34, PMC2656539. RPPPCP
2. WHO. HEPATITIS C. 2002;http://www.who.int/csr/disease/hepatitis/Hepc.pdf
3. Health Protection Agency (Hepatitis C in UK). http://wwwhpaorguk/hepC2009
4. Scotland HP. Hepatitis C in Scotland http://wwwdocumentshpsscotnhsuk/ewr/pdf2009/0918pdf
5. Patel HHE. When to treat and the benefits of treating hepatitis C in patients with haemophilia. Haemophilia. 2009;15(1):20-32.
6. Alter HJPR, Shih JW, Melpolder JC, Houghton M, Choo QL, Kuo G. Detection of antibody to hepatitis C virus in prospectively followed transfusion recipients with acute and chronic non-A, non-B hepatitis. N Engl J Med. 1989 Nov 30;321(22):1494-1500.
7. Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. The Lancet. 1997;349(9055): 825-832.
8. Mattsson LSA, Weiland O. Outcome of acute symptomatic non-A, non-B hepatitis: a 13-year follow-up study of hepatitis C virus markers. Liver. 1993;13;274-278.
9. Tremolada FCC, Alberti A, Drago C, Tagger A, Ribero ML, Realdi G. Long-term follow-up of non-A, non-B (type C) post-transfusion hepatitis. J Hepatol. 1992 Nov;16(3):273-281.
10. Di Bisceglie AMGZ, Ishak KG, Hoofnagle JH, Melpolder JJ, Alter HJ. Long-term clinical and histopathological follow-up of chronic post-transfusion hepatitis. Hepatology. 1991 Dec;14(6):969-974.
11. Koretz RLAH, Coleman E, Gitnick G. Non-A, non-B post-transfusion hepatitis - looking back in the second decade. Ann Intern Med. 1993; 119:110-115.
12. Tong MJ, El-Farra NS, Reikes AR, Co RL. Clinical Outcomes after Transfusion-Associated Hepatitis C. N Engl J Med. 1995 June 1; 332(22):1463-1466.
13. Yano M, Kumada H, Kage M, Ikeda K, Shimamatsu K, Inoue O, et al. The long-term pathological evolution of chronic hepatitis C. Hepatology. 1996;23(6):1334-1340.
14. Kiyosawa KST, Tanaka E, Gibo Y, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: Analysis by detection of antibody to hepatitis C virus. Hepatology. 1990;12(4): 671-675.
15. Niederau CLS, Heintges T, Erhardt A, Buschkamp M, Hürter D, Nawrocki M, Kruska L HF, Petry W, Häussinger D. Prognosis of chronic hepatitis c: Results of a large, prospective cohort study. Hepatology. 1998;28(6):1687-1695.
16. Vogt M, Lang T, Frosner G, Klingler C, Sendl AF, Zeller A, et al. Prevalence and Clinical Outcome of Hepatitis C Infection in Children Who Underwent Cardiac Surgery before the Implementation of Blood-Donor Screening. N Engl J Med. 1999 Sep 16;341(12): 866-870.
17. Seeff LBHF, Alter HJ, Wright EC, et al. Long-term mortality and morbidity of transfusion-associated non-A, non-B, and type C hepatitis: A National Heart, Lung, and Blood Institute collaborative study. Hepatology. 2001;33(2):455-463.
18. Seeff LB, Miller RN, Rabkin CS, Buskell-Bales Z, Straley-Eason KD, Smoak BL, et al. 45-Year Follow-up of Hepatitis C Virus Infection in Healthy Young Adults. Annals of Internal Medicine. 2000 Jan 18;132(2):105-111.
19. Seeff LB. The history of the "natural history" of hepatitis C (1968-2009). Liver International. 2009;29(s1):89-99.
20. Sterling RK, Stravitz RT, Luketic VA, Sanyal AJ, Contos MJ, Mills AS, et al. A comparison of the spectrum of chronic hepatitis C virus between Caucasians and African Americans. Clinical Gastroenterology and Hepatology. 2004;2(6):469-473.
21. Hutchinson SJ, Bird SM, Goldberg DJ. Influence of Alcohol on the Progression of Hepatitis C Virus Infection: A Meta-analysis. Clinical Gastroenterology and Hepatology. 2005;3(11):1150-1159.
22. Westin J, Lagging LM, Spak F, Aires N, Svensson E, Lindh M, et al. Moderate alcohol intake increases fibrosis progression in untreated patients with hepatitis C virus infection. Journal of Viral Hepatitis. 2002;9(3):235-241.
23. Adinolfi LEGM, Andreana A, Tripodi MF, Utili R, Ruggiero G. Steatosis accelerates the progression of liver damage of chronic hepatitis C patients and correlates with specific HCV genotype and visceral obesity. Hepatology. 2001;33(6):1358-1364.
24. Bica I, McGovern B, Dhar R, Stone D, McGowan K, Scheib R, et al. Increasing Mortality Due to End†Stage Liver Disease in Patients with Human Immunodeficiency Virus Infection. Clinical Infectious Diseases. 2001;32(3):492-427.
25. Sulkowski MSMS, Torbenson MS, Higgins Y, et al. Rapid fibrosis progression among HIV/hepatitis C virus-co-infected adults. AIDS. 2007;21(16):2209-2216.
26. Fattovich G, Giustina G, Degos F, Tremolada F, Diodati G, Almasio P, et al. Morbidity and mortality in compensated cirrhosis type C: A retro-spective follow-up study of 384 patients. Gastroenterology. 1997;112(2): 463-472.
27. Kim WR. The burden of hepatitis C in the United States. Hepatology. 2002;36(5B):s30-s4.
28. Foster GR, Goldin RD, Thomas HC. Chronic hepatitis C virus infection causes a significant reduction in quality of life in the absence of cirrhosis. Hepatology. 1998;27(1):209-212.
29. SIGN. Managment of Hepatitis C http://www.sign.ac.uk/pdf/sign92.pdf. 2006.
30. NICE. Hepatitis C http://www.nice.org.uk/TA106. 2006.
31. EASL International Consensus Conference on Hepatitis C Paris, 1999 Feb 26-28: Consensus Statement*. Journal of Hepatology. 1999;30(5): 956-961.
32. Edlin BR, Seal KH, Lorvick J, Kral AH, Ciccarone DH, Moore LD, et al. Is It Justifiable to Withhold Treatment for Hepatitis C from Illicit-Drug Users? N Engl J Med. 2001 Jul 19;345(3):211-214.
33. Chang CH, Chen KY, Lai MY, Chan KA. Meta-analysis: ribavirin-induced haemolytic anaemia in patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics. 2002;16(9): 1623-1632.
34. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Bowers PJ, et al. Once-weekly epoetin alfa improves anemia and facilitates maintenance of ribavirin dosing in hepatitis C virus-infected patients receiving ribavirin plus interferon alfa. Am J Gastroenterol. 2003;98(11):2491-2499.
35. Pockros PJSM, Schiff ER, Sulkowski MS, et al. Proactive Study Group. Epoetin alfa improves quality of life in anemic HCV-infected patients receiving combination therapy. Hepatology. 2004;40(6): 1450-1458.
36. Muir AJMJ. Growth factors during HCV therapy may be "cost- effective", but are they "effective"? Hepatology. 2006;44(6):1400-1403.
37. McHutchison JGGS, Schiff ER, et al Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. New Eng J Med. 1998:339:1485-1492.
38. Poynard TMP, Lee SS, et al. Randomised trial of interferon α2b plus ribavirin for 48 weeks or for 24 weeks versus interferon α2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. Lancet. 1998;352:1426-1432.
39. Kjaegard LL KK, Gluud C. Interferon alfa with or without ribavirin for chronic hepatitis C: Systematic review of randomised trial. BMJ. 2001; 323:1151-1155.
40. Luxon BA, Grace M, Brassard D, Bordens R. Pegylated interferons for the treatment of chronic hepatitis C infection. Clinical Therapeutics. 2002;24(9):1363-1383.
41. Foster GR. Pegylated Interferons for the Treatment of Chronic Hepatitis C: Pharmacological and Clinical Differences between Peginterferon-[alpha]-2a and Peginterferon-[alpha]-2b. Drugs. 70(2): 147-165.
42. Fried MW, Shiffman ML, Reddy KR, Smith C, Marinos G, Goncales FL Jr, et al. Peginterferon Alfa-2a plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J Med. 2002 Sep 26;347(13): 975-982.
43. Manns MP, McHutchison JG, Gordon SC, Rustgi VK, Shiffman M, Reindollar R, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. The Lancet. 2001;358(9286):958-965.
44. Davis G. Monitoring of viral levels during therapy of hepatitis C. Hepatology. 2002;36(5B):s145-s51.
45. Hadziyannis SJ, Sette H, Morgan TR, Balan V, Diago M, Marcellin P, et al. Peginterferon-α2a and Ribavirin Combination Therapy in Chronic Hepatitis C. Annals of Internal Medicine. 2004 Mar 2;140(5): 346-355.
46. Taylor LE, Rich JD, Tashima KT, Gholam PM, Torriani FJ, Dieterich DT, et al. Peginterferon plus Ribavirin for Hepatitis C in HIV-Infected Patients. N Engl J Med. 2004 Nov 25;351(22):2340-2342.
47. Carrat F, Bani-Sadr F, Pol S, Rosenthal E, Lunel-Fabiani F, Benzekri A, et al. Pegylated Interferon Alfa-2b vs Standard Interferon Alfa-2b, Plus Ribavirin, for Chronic Hepatitis C in HIV-Infected Patients: A Randomized Controlled Trial. JAMA. 2004 Dec15;292(23):2839-2848.
48. McHutchison JG, Manns M, Patel K, Poynard T, Lindsay KL, Trepo C, et al. Adherence to combination therapy enhances sustained response in genotype-1-infected patients with chronic hepatitis C. Gastroenterology. 2002;123(4):1061-1069.
49. McHutchison J, Sulkowski M. Scientific rationale and study design of the individualized dosing efficacy vs flat dosing to assess optimal pegylated interferon therapy (IDEAL) trial: determining optimal dosing in patients with genotype 1 chronic hepatitis C. Journal of Viral Hepatitis. 2008;15(7):475-481.
50. Awad T TK, Hauser G, Stimac D, Mabrouk M, Gluud C. Peginterferon alpha-2a is associated with higher sustained virological response than peginterferon alfa-2b in chronic hepatitis C: Systematic review of randomized trials. Hepatology. 51(4):1176-1184.
51. Poynard T, Cacoub P, Ratziu V, Myers RP, Dezailles MH, Mercadier A, et al. Fatigue in patients with chronic hepatitis C. Journal of Viral Hepatitis. 2002;9(4):295-303.
52. Ware JE Jr., BM, Mannocchia M, Davis GL, International Hepatitis Interventional Therapy G. Health-related quality of life in chronic hepatitis C: Impact of disease and treatment response. Hepatology. 1999;30(2):550-555.
53. Younossi ZM, Guyatt G, Kiwi M, Boparai N, King D. Development of a disease specific questionnaire to measure health related quality of life in patients with chronic liver disease. Gut. 1999 Aug 1;45(2):295-300.
54. Younossi ZKJ, Kincaid J. The effects of HCV infection and management on health-related quality of life. Hepatology. 2007;45(3):806-816.
55. Bonkovsky HLWJ. Group CIS. Reduction of health-related quality of life in chronic hepatitis C and improvement with interferon therapy. Hepatology. 1999;29(1):264-270.
56. Carithers RL Jr. SD, Bayliss M. Health assessment for chronic HCV infection: results of quality of life. Dig Dis Sci. 1996 Dec;41 Suppl 12:75S-80S. PubMed PMID.
57. Forton DMTH, Murphy CA, Allsop JM, Foster GR, Main J, Wesnes KA, SDTR. Hepatitis C and cognitive impairment in a cohort of patients with mild liver disease. Hepatology. 2002;35(2):433-439.
58. Neary MPCS, Bayliss MS, Ware JE Jr. Sustained virologic response is associated with improved health-related quality of life in relapsed chronic hepatitis C patients. Semin Liver Dis. 1999;19 Suppl 1:77-85.
59. Fontana RJ, Hussain KB, Schwartz SM, Moyer CA, Su GL, Lok ASF. Emotional distress in chronic hepatitis C patients not receiving antiviral therapy. Journal of Hepatology. 2002;36(3):401-407.
60. Negro F. Adverse effects of drugs in the treatment of viral hepatitis. Best Practice and Research Clinical Gastroenterology. 24(2):183-192.
61. Bernfort L, Sennfãelt K, Reichard O. Cost-effectiveness of peginterferon alfa-2b in combination with ribavirin as initial treatment for chronic hepatitis C in Sweden. Scandinavian Journal of Infectious Diseases. 2006;38(6-7):497-505.
62. Siebert U, Sroczynski G, Rossol S, Wasem J, Ravens-Sieberer U, Kurth BM, et al. Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C. Gut. 2003 Mar;52(3):425-432.
63. Wong JB, Davis GL, Pauker SG. Cost effectiveness of ribavirin/ interferon alfa-2b after interferon relapse in chronic hepatitis C. The American Journal of Medicine. 2000;108(5):366-373.
64. Buti M, Medina M, Casado MA, Wong JB, Fosbrook L, Esteban R. A cost-effectiveness analysis of peginterferon alfa-2b plus ribavirin for the treatment of naive patients with chronic hepatitis C. Alimentary Pharmacology and Therapeutics. 2003;17(5):687-694.
65. Shepherd JBH, Cave CB, Waugh NR, Price A, Gabbay J. Clinical - and cost-effectiveness of pegylated interferon alfa in the treatment of chronic hepatitis C: a systematic review and economic evaluation. Int J Technol Assess Health Care. 2005 Winter:21(1):47-54.
66. Sheerin IG, Green FT, Sellman JD. What is the cost-effectiveness of hepatitis C treatment for injecting drug users on methadone maintenance in New Zealand? Drug and Alcohol Review. 2004;23(3):261-272.
67. Grishchenko M, Grieve RD, Sweeting MJ, de Angelis D, Thomson BJ, Ryder SD, et al. Cost-effectiveness of pegylated interferon and ribavirin for patients with chronic hepatitis C treated in routine clinical practice. International Journal of Technology Assessment in Health Care. 2009;25(02):171-180.
68. McCowan C, Kidd B, Fahey T. Factors associated with mortality in Scottish patients receiving methadone in primary care: retrospective cohort study. BMJ. 2009 Jun 16;338(jun16_4):b2225.
69. Zeuzem SPJ, Lukasiewicz E, et al. DITTO-HCV Study Group. Interna-tional, multicenter, randomized, controlled study comparing dynami-cally individualized versus standard treatment in patients with chronic hepatitis C. J Hepatol. 2005 Aug;43(2):250-257.
70. Diago MSM, Bronowicki JP, Zeuzem S, Rodriguez-Torres M, Pappas SC, Tietz AND. Identifying hepatitis C virus genotype 2/3 patients who can receive a 16-week abbreviated course of peginterferon alfa-2a (40KD) plus ribavirin. Hepatology. 9999(9999):NA.
71. Berman K, Kwo PY. Boceprevir an NS3 Protease Inhibitor of HCV. Clinics in Liver Disease. 2009;13(3):429-439.
72. McHutchison JGEG, Gordon SC, Jacobson IM, et al. PROVE1 Study Team. Telaprevir with Peginterferon and Ribavirin for Chronic HCV Genotype 1 Infection. N Engl J Med. 2009 Oct 8;361(15):1516.